

MEDIMMUNE IN EXCLUSIVE AGREEMENT WITH VIROSOME

Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that Norwood Immunology Ltd (NIM) has announced that its subsidiary, Virosome Biologicals NV, has entered into an exclusive evaluation agreement with MedImmune LLC, a wholly-owned member of the AstraZeneca Group.

The agreement relates to Virosome's virosomal vaccine technology. The full text of the Norwood Immunology Ltd announcement is reproduced below.

AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines marketed globally. AstraZeneca reported annual sales of nearly \$30 billion in 2007 and a net profit of \$9 billion.

MedImmune is focussed on the areas of infectious diseases, cancer and inflammatory diseases. MedImmune was acquired by AstraZeneca in 2007 for \$15.6 billion.

"Norwood Immunology Limited and its subsidiaries ('Norwood Immunology' or 'the Group') (AIM:NIM), the Group focused on stem cell therapies, the rejuvenation and repair of the immune system and the development of virosomal vaccines, today announces that it has signed a six month exclusive evaluation agreement for NIM's virosomal vaccine technology with MedImmune, a recognized leader in vaccine research and development.

Under the terms of this agreement, the Group has agreed to an exclusive collaboration period with MedImmune of six months in exchange for an exclusivity fee and the reimbursement of certain costs associated with performing collaborative research programmes using certain MedImmune vaccine candidates and the Group's virosome technology.

Richard Williams, CEO of Norwood Immunology, commented: "This agreement is indicative of the attractiveness of the Virosomal Biological's adjuvanted virosome technology to major vaccine partners. We look to build on this second vaccine partnership with a major pharmaceutical company and anticipate seeking partners for our preclinical package for Herpes Simplex Virus (HSV) in the second half of 2008."

Norwood Abbey Ltd continues to hold 48.6 million shares in Norwood Immunology Ltd, representing approximately 21% of the company.

To find out more about the Norwood group, visit www.norwoodabbey.com

For further information please contact:

Norwood Abbey Ltd
+61-3-9770-0063